Mirabegron, a Selective β3-Adrenergic Receptor Agonist, as a Potential Anti-Obesity Drug
Journal of Clinical Medicine · 02.11.2023 · 12 (21) · 6897
DOI: 10.3390/jcm12216897 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 02.11.2023. Verfasst von Anna Maria Dąbrowska und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Toxicology, Medical University of Lublin, Jaczewskiego Street 8b, 20-090 Lublin, Poland. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Obesity is becoming a global health epidemic. Brown and “beige” adipose tissue may produce heat, leading to energy expenditure enhancement and weight loss. Mirabegron, a selective β3-adrenergic receptor agonist, has been found to be effective as a brown adipose tissue activator, a “beige” cells stimulator and a metabolic homeostasis controller in animal and human studies. Although in animal studies, administration of mirabegron led to obesity improvement, significant weight loss in obese patients after mirabegron treatment has not been demonstrated so far, which may be associated with the too-short duration of the trials and the small number of participants in the studies. In humans, the most effective treatment for adipose tissue stimulation was high doses of mirabegron; however, cardiovascular side effects may limit the use of such doses, so the long-term safety must be evaluated. In cases of tachycardia or blood pressure elevation, the co-administration of a β1-adrenergic receptor blocker may be useful. It should be checked whether smaller doses of mirabegron, taken for a longer time, will be sufficient to stimulate brown and “beige” adipose tissue, leading to weight loss. The introduction of mirabegron into obesity treatment in the future will require long-term trials with larger numbers of subjects, to assess mirabegron efficacy, tolerability, and safety.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Toxicology, Medical University of Lublin, Jaczewskiego Street 8b, 20-090 Lublin, Poland.
- Endocrinology Outpatient Clinic, Lublin, Poland.
ORCID-Profile: Anna Maria Dąbrowska
Zitieren
APA
Dąbrowska, A. M., & Dudka, J. (2023). Mirabegron, a Selective β3-Adrenergic Receptor Agonist, as a Potential Anti-Obesity Drug. Journal of Clinical Medicine, 12(21), 6897. https://doi.org/10.3390/jcm12216897
Vancouver
Dąbrowska AM, Dudka J. Mirabegron, a Selective β3-Adrenergic Receptor Agonist, as a Potential Anti-Obesity Drug. Journal of Clinical Medicine. 2023;12(21):6897. doi:10.3390/jcm12216897
BibTeX
@article{Dbrowska2023,
author = {Dąbrowska, Anna Maria and Dudka, Jarosław},
title = {Mirabegron, a Selective β3-Adrenergic Receptor Agonist, as a Potential Anti-Obesity Drug},
journal = {Journal of Clinical Medicine},
year = {2023},
volume = {12},
number = {21},
pages = {6897},
doi = {10.3390/jcm12216897}
}
EUVIMED